Effect of Pimobendan on NT-proBNP and c troponin I before and after a submaximal exercise test in dogs with preclinical mitral valve disease without cardiomegaly - a randomised, double-blinded trial.
Animals
Biomarkers
/ blood
Dog Diseases
/ blood
Dogs
Exercise Test
/ veterinary
Female
Heart Valve Diseases
/ blood
Male
Natriuretic Peptide, Brain
/ blood
Peptide Fragments
/ blood
Physical Conditioning, Animal
/ physiology
Pyridazines
/ pharmacology
Random Allocation
Stress, Physiological
/ drug effects
Treatment Outcome
Troponin I
/ blood
Cardiac biomarkers
Dog
Exercise test
Mitral valve disease
Pimobendan
Journal
BMC veterinary research
ISSN: 1746-6148
Titre abrégé: BMC Vet Res
Pays: England
ID NLM: 101249759
Informations de publication
Date de publication:
09 Jul 2019
09 Jul 2019
Historique:
received:
26
09
2018
accepted:
26
06
2019
entrez:
11
7
2019
pubmed:
11
7
2019
medline:
29
9
2019
Statut:
epublish
Résumé
Exercise testing in conjunction with measurement of cardiac biomarkers NT-proBNP and cTnI is a useful tool for monitoring the effect of treatment on cardiac patients. Administering Pimobendan in dogs with degenerative mitral valve disease (DMVD) and cardiomegaly results in delaying the onset of clinical symptoms and prolonging life. Its effect in dogs with DMVD without cardiomegaly has not been well examined. The aim of the current study was to investigate the effect of administering Pimobendan in dogs with DMVD without cardiomegaly using exercise testing in conjunction with measuring cardiac biomarkers in addition to echocardiography. Twenty-one dogs with asymptomatic DMVD without echocardiographic signs of cardiomegaly participated in a randomised, double-blinded trial. Dogs were divided into a Pimobendan-group (n = 11) and a placebo-group (n = 10) in a double-blinded study design and underwent a standardised submaximal exercise test (SSET). One dog in the Pimobendan-group was retrospectively removed from the study after being diagnosed with Leishmaniosis. Cardiac biomarkers NT-proBNP and cTnI were measured before and after exercise. Follow-up appointments were performed at days 90 and 180. Dogs in the Pimobendan-group had significantly lower post-exercise NT-proBNP-levels after being administered Pimobendan than at the beginning of the study. They also had lower pre- and post-exercise-NT-proBNP-levels than those dogs in the placebo-group. There was neither a significant difference regarding the measured cTnI levels nor an increase in cTnI between the groups at any time. Pimobendan lowers NT-proBNP in dogs with presymptomatic mitral valve disease without cardiomegaly before and after submaximal exercise. This indicates a reduction in cardiac wall stress. If dogs with asymptomatic DMVD without cardiomegaly benefit from treatment with Pimobendan (for example, through a longer survival time) warrants further investigation.
Sections du résumé
BACKGROUND
BACKGROUND
Exercise testing in conjunction with measurement of cardiac biomarkers NT-proBNP and cTnI is a useful tool for monitoring the effect of treatment on cardiac patients. Administering Pimobendan in dogs with degenerative mitral valve disease (DMVD) and cardiomegaly results in delaying the onset of clinical symptoms and prolonging life. Its effect in dogs with DMVD without cardiomegaly has not been well examined. The aim of the current study was to investigate the effect of administering Pimobendan in dogs with DMVD without cardiomegaly using exercise testing in conjunction with measuring cardiac biomarkers in addition to echocardiography. Twenty-one dogs with asymptomatic DMVD without echocardiographic signs of cardiomegaly participated in a randomised, double-blinded trial. Dogs were divided into a Pimobendan-group (n = 11) and a placebo-group (n = 10) in a double-blinded study design and underwent a standardised submaximal exercise test (SSET). One dog in the Pimobendan-group was retrospectively removed from the study after being diagnosed with Leishmaniosis. Cardiac biomarkers NT-proBNP and cTnI were measured before and after exercise. Follow-up appointments were performed at days 90 and 180.
RESULTS
RESULTS
Dogs in the Pimobendan-group had significantly lower post-exercise NT-proBNP-levels after being administered Pimobendan than at the beginning of the study. They also had lower pre- and post-exercise-NT-proBNP-levels than those dogs in the placebo-group. There was neither a significant difference regarding the measured cTnI levels nor an increase in cTnI between the groups at any time.
CONCLUSIONS
CONCLUSIONS
Pimobendan lowers NT-proBNP in dogs with presymptomatic mitral valve disease without cardiomegaly before and after submaximal exercise. This indicates a reduction in cardiac wall stress. If dogs with asymptomatic DMVD without cardiomegaly benefit from treatment with Pimobendan (for example, through a longer survival time) warrants further investigation.
Identifiants
pubmed: 31288807
doi: 10.1186/s12917-019-1980-z
pii: 10.1186/s12917-019-1980-z
pmc: PMC6617668
doi:
Substances chimiques
Biomarkers
0
Peptide Fragments
0
Pyridazines
0
Troponin I
0
pro-brain natriuretic peptide (1-76)
0
Natriuretic Peptide, Brain
114471-18-0
pimobendan
34AP3BBP9T
Types de publication
Clinical Trial, Veterinary
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
237Références
Curr Control Trials Cardiovasc Med. 2001;2(2):75-84
pubmed: 11806777
Vet Radiol Ultrasound. 2002 Nov-Dec;43(6):568-75
pubmed: 12502113
Eur J Heart Fail. 2004 Mar 15;6(3):257-60
pubmed: 14987573
J Vet Intern Med. 2004 May-Jun;18(3):311-21
pubmed: 15188817
Cardiovasc Toxicol. 2005;5(1):43-51
pubmed: 15738584
Ann Intern Med. 2005 May 3;142(9):786-91
pubmed: 15867411
Am Heart J. 2005 Dec;150(6):1128-34
pubmed: 16338248
Heart. 2006 Jun;92(6):843-9
pubmed: 16698841
J Vet Intern Med. 2007 Jul-Aug;21(4):742-53
pubmed: 17708394
J Am Vet Med Assoc. 2008 May 15;232(10):1496-503
pubmed: 18479239
Med Sci Sports Exerc. 2008 Aug;40(8):1408-15
pubmed: 18614952
J Vet Intern Med. 2008 Sep-Oct;22(5):1124-35
pubmed: 18638016
Aust Vet J. 2008 Oct;86(10):390-4
pubmed: 18826510
J Vet Cardiol. 2009 May;11 Suppl 1:S93-7
pubmed: 19395335
J Vet Intern Med. 2009 Sep-Oct;23(5):984-94
pubmed: 19572913
J Vet Intern Med. 2009 Nov-Dec;23(6):1142-50
pubmed: 19780929
Postgrad Med J. 2009 Oct;85(1008):538-45
pubmed: 19789193
Physiol Res. 2010;59(4):625-8
pubmed: 19929142
Coron Artery Dis. 2010 Jun;21(4):244-56
pubmed: 20351549
Eur J Heart Fail. 2012 Nov;14(11):1293-302
pubmed: 22782970
Vet Clin Pathol. 2012 Dec;41(4):568-74
pubmed: 22971249
Vet Clin Pathol. 2013 Jun;42(2):196-206
pubmed: 23614733
J Vet Intern Med. 2013 Nov-Dec;27(6):1441-51
pubmed: 24010489
Eur Heart J. 2014 Jun 21;35(24):1608-16
pubmed: 24014387
Vet Clin North Am Small Anim Pract. 2013 Nov;43(6):1261-72, vi
pubmed: 24144089
J Cardiovasc Pharmacol. 1989;14 Suppl 2:S1-6
pubmed: 2478784
J Vet Intern Med. 2015 Jan;29(1):171-9
pubmed: 25308881
Naunyn Schmiedebergs Arch Pharmacol. 1989 May;339(5):575-83
pubmed: 2549430
J Clin Pharmacol. 1989 Apr;29(4):360-6
pubmed: 2723124
J Vet Intern Med. 2016 Nov;30(6):1765-1779
pubmed: 27678080
J Clin Med Res. 2016 Nov;8(11):797-804
pubmed: 27738481
J Vet Intern Med. 2018 Jan;32(1):72-85
pubmed: 29214723
PLoS One. 2018 Jun 14;13(6):e0199023
pubmed: 29902265
J Mol Cell Cardiol. 1987 Oct;19(10):999-1010
pubmed: 3437457